JP2023503472A5 - - Google Patents

Info

Publication number
JP2023503472A5
JP2023503472A5 JP2022530716A JP2022530716A JP2023503472A5 JP 2023503472 A5 JP2023503472 A5 JP 2023503472A5 JP 2022530716 A JP2022530716 A JP 2022530716A JP 2022530716 A JP2022530716 A JP 2022530716A JP 2023503472 A5 JP2023503472 A5 JP 2023503472A5
Authority
JP
Japan
Prior art keywords
amino acid
seq
gdf15
acid sequence
variant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022530716A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023503472A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/KR2020/016842 external-priority patent/WO2021107603A2/en
Publication of JP2023503472A publication Critical patent/JP2023503472A/ja
Publication of JP2023503472A5 publication Critical patent/JP2023503472A5/ja
Pending legal-status Critical Current

Links

JP2022530716A 2019-11-26 2020-11-25 長時間作用型gdf15融合タンパク質およびそれを含む医薬組成物 Pending JP2023503472A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20190153680 2019-11-26
KR10-2019-0153680 2019-11-26
PCT/KR2020/016842 WO2021107603A2 (en) 2019-11-26 2020-11-25 Long-acting gdf15 fusion protein and pharmaceutical composition comprising same

Publications (2)

Publication Number Publication Date
JP2023503472A JP2023503472A (ja) 2023-01-30
JP2023503472A5 true JP2023503472A5 (cg-RX-API-DMAC7.html) 2023-12-04

Family

ID=76130664

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022530716A Pending JP2023503472A (ja) 2019-11-26 2020-11-25 長時間作用型gdf15融合タンパク質およびそれを含む医薬組成物

Country Status (11)

Country Link
US (1) US20230002460A1 (cg-RX-API-DMAC7.html)
EP (1) EP4065597A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023503472A (cg-RX-API-DMAC7.html)
KR (1) KR20210065057A (cg-RX-API-DMAC7.html)
CN (1) CN114729020A (cg-RX-API-DMAC7.html)
AU (1) AU2020394255B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022010227A2 (cg-RX-API-DMAC7.html)
CA (1) CA3161302A1 (cg-RX-API-DMAC7.html)
MX (1) MX2022006173A (cg-RX-API-DMAC7.html)
WO (1) WO2021107603A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA202204624B (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4351627A4 (en) * 2021-05-21 2025-06-04 Yuhan Corporation COMPOSITION FOR COMBINATION THERAPY COMPRISING A GROWTH DIFFERENTIATION FACTOR 15 VARIANT AND A GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONIST
AU2022278933A1 (en) * 2021-05-21 2023-12-07 Yuhan Corporation Composition for preventing or treating non-alcoholic fatty liver disease or non-alcoholic steatohepatitis comprising growth differentiation factor-15 variant
US20240350588A1 (en) * 2021-08-24 2024-10-24 Sunshine Lake Pharma Co., Ltd. Gdf15 fusion proteins and use thereof
EP4619423A1 (en) * 2022-11-18 2025-09-24 Yuhan Corporation Dual function proteins and uses thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5288931A (en) * 1991-12-06 1994-02-22 Genentech, Inc. Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation
GB9912350D0 (en) * 1999-05-26 1999-07-28 European Molecular Biology Lab Embl Modified cytokine
FI117667B (fi) * 2001-07-05 2007-01-15 Univ Zuerich Farmaseuttinen koostumus, joka soveltuu käytettäväksi ortopediassa ja hammaslääketieteessä
DK2441466T3 (da) 2004-04-13 2014-10-27 St Vincents Hosp Sydney MIC-1-inhiberende middel
EP1861419B1 (en) * 2005-03-15 2011-06-29 Allergan, Inc. Modified clostridial toxins with enhanced targeting capabilities for endogenous clostridial toxin receptor systems
ES2627337T3 (es) * 2010-08-26 2017-07-27 F. Hoffmann-La Roche Ag Uso de biomarcadores para controlar una medicación en un sujeto que padece insuficiencia cardíaca
WO2012106615A1 (en) * 2011-02-03 2012-08-09 Xoma Technology Ltd. Methods and materials for enhancing functional protein expression in bacteria
KR20140125803A (ko) * 2012-01-26 2014-10-29 암젠 인크 성장 분화 인자 15(gdf-15) 폴리펩타이드들
CA2899170C (en) * 2013-01-30 2022-08-02 Ngm Biopharmaceuticals, Inc. Compositions and methods of use in treating metabolic disorders
US9161966B2 (en) * 2013-01-30 2015-10-20 Ngm Biopharmaceuticals, Inc. GDF15 mutein polypeptides
LT3027642T (lt) * 2013-07-31 2020-10-12 Amgen Inc. Augimo ir diferenciacijos faktoriaus 15(gdf-15) konstruktai
WO2015197446A1 (en) * 2014-06-24 2015-12-30 Novo Nordisk A/S Mic-1 fusion proteins and uses thereof
JP6704358B2 (ja) * 2014-07-30 2020-06-03 エヌジーエム バイオファーマシューティカルズ インコーポレイテッド 代謝障害を治療するための組成物および使用方法
AU2015339134B2 (en) * 2014-10-30 2021-06-17 Acceleron Pharma Inc. Methods and compositions using GDF15 polypeptides for increasing red blood cells
CN106687128B (zh) * 2014-10-31 2022-05-10 Ngm生物制药有限公司 用于治疗代谢病症的组合物和方法
US10336812B2 (en) * 2016-05-10 2019-07-02 Janssen Biotech, Inc. GDF15 fusion proteins and uses thereof
KR101727506B1 (ko) * 2016-07-14 2017-05-04 충남대학교 산학협력단 Gdf15 단백질 또는 이를 암호화하는 폴리뉴클레오티드를 유효성분으로 함유하는 지방간의 예방 또는 치료용 약학적 조성물

Similar Documents

Publication Publication Date Title
CN115003689A (zh) 具有改变的表面残基的经设计的锚蛋白重复结构域
AU2016289492B2 (en) Vaccine against RSV
AU2016289496B2 (en) Stabilized soluble pre-fusion RSV F polypeptides
CN103403024B (zh) 设计的锚蛋白重复蛋白的改进的n‑端加帽模块
ES2646614T3 (es) Uso de un compuesto de FGF 21 y un compuesto de GLP 1 para el tratamiento de la obesidad
CN114206908B (zh) 具有改善的稳定性的经设计的锚蛋白重复结构域
JP2023504914A5 (cg-RX-API-DMAC7.html)
JP2014510518A5 (cg-RX-API-DMAC7.html)
RU2015110250A (ru) ВАРИАНТЫ FcγRIIB-СПЕЦИФИЧЕСКОЙ Fc-ОБЛАСТИ
KR960700340A (ko) 안정한 살균/투과성-증가 단백질 생성물 및 그를 포함하는 제약학적 조성물(stable bactericidal/permeability-increasing protein products and pharmaceutical compositions containing the same)
HRP20110714T1 (hr) Fuzijski proteini analoga glp-1
WO2014165093A9 (en) Fibronectin based scaffold domains linked to serum albumin or a moiety binding thereto
HRP20201392T1 (hr) Fgf21 fuzijski proteini dugotrajnog djelovanja i farmaceutski pripravci koji sadrže iste
EP4582442A3 (en) Tnfr2 agonists with improved stability
JP2015504052A5 (cg-RX-API-DMAC7.html)
JP2020517260A5 (cg-RX-API-DMAC7.html)
WO2009031835A4 (en) Cell permeable nm23 recombinant proteins, polynucleotides encoding the same, and anti-metastatic composition comprising the same
JP2023503472A (ja) 長時間作用型gdf15融合タンパク質およびそれを含む医薬組成物
JP2005511038A5 (cg-RX-API-DMAC7.html)
JP2019518713A5 (cg-RX-API-DMAC7.html)
Schröder et al. Primary structure of the neuronal clathrin‐associated protein auxilin and its expression in bacteria
RU2007119376A (ru) Тимус - специфический белок
JPWO2023282281A5 (cg-RX-API-DMAC7.html)
JP2023544300A5 (cg-RX-API-DMAC7.html)
EP2597102A1 (en) A novel fusion protein comprising an antibody light chain and a polypeptide binding to IL-17